-
Collaboration to Boost Rare Disease Clinical Trials
An organization seeking new uses for today’s drugs and a contract research company aim to increase the number of clinical trials for rare diseases testing already approved drugs.
-
Quantum Technology Start-Up Accelerator Unveiled
A business incubator is underway to help start-up enterprises in Denmark working in quantum technologies, particularly with defense-related applications.
-
$15M Alternative Chicken, Fish Challenge Finalists Named
An international challenge competition seeking sustainable but realistic alternatives to natural chicken and fish protein named its six finalist teams.
-
Digital Diabetes System Shown to Cut Health Care Use
A study of people with type 2 diabetes shows those using a digital diabetes management system made fewer hospital visits than non-users over a 12-month period.
-
Computational Drug Discovery Company Acquires A.I. Businesses
Two companies using artificial intelligence to advance biotechnology and design new therapies are merging with a computational-engineering drug discovery enterprise.
-
Infographic – Psychedelics Funding Coming Down
Technology intelligence company CB Insights says this week that psychedelic therapies and services are generating little interest among venture investors this year, with only nine deals totaling $21 million.
-
Crispr Therapy Shown to Remove E. Coli in Gut
New research with lab animals shows gene-edited viruses can target and remove harmful E. coli bacteria from the gut, including strains usually resistant to antibiotics.
-
Trial Underway Testing Psychedelic Drug for Depression
The first participant in a clinical trial received a dose of a psychedelic therapy, assessing the experimental compound in people with treatment resistant depression.
-
DNA Test Detects Early Bladder Cancer in Urine
A genomic analysis of urine samples is shown to predict the most common form of bladder cancer years before symptoms appear.
-
Biotech to Design Disease-Blocking Drugs, Gains $75M
A new company that says it can stop disease-causing proteins from forming in cells began public operations today, and is raising $75 million in its first venture round.